背景：随着新发癌症病例和死亡率的增加，癌症已成为严重的全球健康问题，但目前还没有理想的癌症生物标记物用于有效诊断。目前，越来越多的证据表明长非编码RNA（lncRNA）在癌症进展中起着基础性的作用。BBOX1反义RNA 1（BBOX1-AS1）是最近被确认的一种lncRNA，在各种癌症中被发现异常表达，并且与癌症患者的生存率下降有关。方法：我们彻底搜索了六个数据库，包括截至2023年4月27日发表的合格文章。通过比值比（OR）和带有95％置信区间的风险比来评估BBOX1-AS1表达水平与预后和临床病理参数的关联。此外，我们还利用GEPIA在线数据库对结果进行了进一步验证。结果：包括602名患者的八项研究纳入了本分析。相较于低BBOX1-AS1表达，高BBOX1-AS1表达意味着较差的总体生存率（风险比=2.30，95％Cl [1.99, 2.67]，p < 0.00001）。此外，BBOX1-AS1表达与淋巴结转移（OR = 3.00，95％CI [1.71-5.28]，p = 0.0001）和晚期肿瘤分期（OR = 3.74，95％CI [2.63-5.32]，p < 0.00001）呈正相关。此外，BBOX1-AS1在12种恶性肿瘤中明显上调，并且通过GEPIA在线基因分析工具进一步证实了升高的BBOX1-AS1表达与较差的总体生存率和恶性疾病无瘤生存期。结论：这些发现强调了BBOX1-AS1与不利的总体生存率、疾病无瘤生存期、淋巴结转移和肿瘤分期显著相关，因此，它可能作为一种新的有前景的生物标志物来预测各种癌症的临床病理特征和预后。版权所有 © 2023 Lin、Wang、Deng和Ye。

Background: With the increasing number of new cancer cases and mortality rates, cancer has become a serious global health problem, but there are no ideal cancer biomarkers for effective diagnosis. Currently, mounting evidence demonstrates that lncRNAs play a fundamental role in cancer progression. BBOX1 anti-sense RNA 1 (BBOX1-AS1) is a recently clarified lncRNA and has been identified as dysregulated in various carcinomas, and it contributes to poor survival in cancer patients. Methods: We thoroughly searched six databases for eligible articles published as of 27, April 2023. The association of BBOX1-AS1 expression levels with prognostic and clinicopathological parameters was assessed by odds ratios (OR) and hazard ratios with 95% CIs. Additionally, we further validated our results utilizing the GEPIA online database. Results: Eight studies comprising 602 patients were included in this analysis. High BBOX1-AS1 expression indicated poor overall survival (OS) (hazard ratios = 2.30, 95% Cl [1.99, 2.67], p < 0.00001) when compared with low BBOX1-AS1 expression. Furthermore, BBOX1-AS1 expression was positively correlated with lymph node metastasis (OR = 3.00, 95% CI [1.71-5.28], p = 0.0001) and advanced tumor stage (OR = 3.74, 95% CI [2.63-5.32], p < 0.00001) for cancer patients. Moreover, BBOX1-AS1 was remarkably upregulated in 12 malignancies, and the elevated BBOX1-AS1 expression predicted poorer OS and worse disease-free survival (DFS) confirmed through the GEPIA online gene analysis tool. Conclusion: The findings highlight that BBOX1-AS1 was significantly associated with detrimental overall survival, disease-free survival, lymph node metastasis and tumor stage; thus, it could act as a novel promising biomarker to predict the clinicopathological characteristics and prognosis for various cancers.Copyright © 2023 Lin, Wang, Deng and Ye.